During last month’s European Society for Medical Oncology Asia 2018 annual meeting, held in Singapore from November 23 to November 25, researchers presented data demonstrating the biosimilarity of QL1101 with reference bevacizumab (Avastin).
During last month’s European Society for Medical Oncology’s Asia 2018 annual meeting, held in Singapore from November 23 to November 25, researchers presented data demonstrating the biosimilarity of QL1101 with reference bevacizumab (Avastin).
QL1101 is a biosimilar product being developed by Chinese drug developer Qilu Pharmaceutical, which funded the phase 3 clinical trial that enrolled 532 patients with nonsquamous non—small-cell lung cancer (NSCLC). The objective of the study was to evaluate the effectiveness of the proposed biosimilar versus the reference bevacizumab.
The patients were randomized to receive either the proposed biosimilar (n = 266) or the reference product (n = 266), and both groups received their therapy in combination with paclitaxel and carboplatin every 3 weeks as a single treatment for 6 cycles. After the 6 cycles were completed, both groups received QL1101 as monotherapy maintenance treatment until disease progression, intolerable toxicity, initiation of a different treatment, loss to follow-up, or death. The primary end point was the best objective response rate (ORR) evaluated by the blind independent imaging review committee at week 18.
At week 18, the ORR of the biosimilar group was 52.26%, with 0 patients achieving a complete response (CR) and 139 patients achieving a partial response (PR). The ORR in the reference group was 56.02%, with 1 patient achieving CR, and 148 achieving PR. The risk ratio value was 0.917 (90% CI, 0.807-1.043), which fell within the prespecified equivalence margin of 0.75 to 1.33.
The researchers reported that the incidences of treatment-related adverse events (AEs) and immunogenicity were similar between the 2 treatment groups, and that no neutralizing antibodies to bevacizumab were detected. No unexpected serious AEs were observed.
The authors concluded that QL1101 and its reference are equivalent in clinical efficacy in nonsquamous NSCLC and that the safety profiles of the 2 drugs are similar.
Reference
Han B, Li K, Chu T, et al. A multi-center, randomized, double-blind, parallel, two-group phase iii trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer. Presented at: European Society for Medical Oncology Asia 2018 Congress; November 23-25, 2018; Singapore. Abstract 396O. cslide.ctimeetingtech.com/asia2018/attendee/confcal/session/calendar?q=biosimilar.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.